Merck's Fosamax Patent Reinstated In E.U.

Law360, New York (March 29, 2007, 12:00 AM EDT) -- In a surprise victory for Merck & Co., the European Patent Office reinstated Wednesday the drug maker's critical patent for its osteoporosis drug Fosamax Once Weekly, nearly three years after it was first declared invalid.

In 2004, the EPO revoked a critical patent for Fosamax’ once weekly treatment that would have expired in 2018. Based on other patents, Fosamax was still protected in most major European markets until around 2007.

But Merck won a reversal of fortunes when the office approved a new filing for the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.